secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001739410-25-000131
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025
--------------------------------------------------------------------------------

- Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).
- Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.
- Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.
- Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.
- RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/0001739410-25-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer